StockData

Rockwell Automation vs Teradyne

ROK and TER side by side, both in laboratory apparatus and analytical, optical, measuring, and controlling instruments. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ROK and TER compare

Rockwell Automation and Teradyne are about the same size, with market caps of $48.4B and $42.9B.

On earnings, Teradyne is cheaper: it trades at 31.5× trailing earnings, against 40.9× for Rockwell Automation.

Teradyne grew revenue faster over the last twelve months (74.9% versus 11.3% for Rockwell Automation).

Teradyne keeps more of each dollar of sales as profit, with a net margin of 27.5% compared with 13.4% at Rockwell Automation.

Both pay dividends: Rockwell Automation yields 1.3% and Teradyne 0.19%.

Teradyne scores higher on the StockData Score (20 against 17 for Rockwell Automation), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricROKTER
Size and price
Market cap$48.4B$42.9B
Share price$436.20$274.37
Change, 1 year18.5%57.7%
Change, 5 years28.7%90.2%
Beta (5Y)1.121.62
Employees23K6,600
StockData Score
Total score1720 (better)
Valuation score13 (better)
Growth score33
Performance score45 (better)
Health score56 (better)
Dividend score4 (better)3
Valuation
P/E40.9×31.5× (better)
P/S5.4× (better)8.6×
P/B13.9×11.6× (better)
EV/EBITDA21.7× (better)24.3×
P/FCF32.2× (better)41.9×
FCF yield3.1% (better)2.4%
Fair value$438.14$295.83
Margin of safety0.44%7.3% (better)
Growth
Revenue growth (TTM)11.3%74.9% (better)
Revenue growth, 5Y average5.7% (better)0.44%
Net income growth (TTM)23.7%210% (better)
EPS growth (TTM)25.2%217% (better)
EPS growth, 5Y average−2.6% (better)−4.1%
Profitability
Gross margin49.1%59.3% (better)
Operating margin22.7%32.1% (better)
Net margin13.4%27.5% (better)
FCF margin16.8%20.5% (better)
Return on equity34.5%42.9% (better)
Return on invested capital26.6%47.3% (better)
Financial health
Debt / equity0.93 (better)0.00
Net debt / EBITDA1.18 (better)−0.26
Interest coverage14.7×147× (better)
Current ratio1.082.08 (better)
Altman Z-score6.0117.66 (better)
Piotroski F-score7 (better)6
Dividends and buybacks
Dividend yield1.3% (better)0.19%
Payout ratio50.9%5.8%
Years of dividend growth16 (better)0
Dividend growth, 5Y average5.1% (better)3.7%
Buyback yield1.7% (better)0.83%
Shareholder yield3.0% (better)1.0%
Ownership
Held by institutions89.2%97.3%
Held by insiders0.29%0.25%
Insider net buying, 12 months−$64.6M−$14.1M (better)
Superinvestors holding11
Short interest, % of float3.3%5.5%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.